12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against Avastin bevacizumab from Roche for first-line treatment of advanced ovarian cancer in combination with paclitaxel and carboplatin. The FAD is in line with a December preliminary appraisal, in which NICE estimated that the incremental cost-effectiveness ratio...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >